TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29499745

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment, traditional EA treatment with de-qi sensation, 3 times per week for 12 sessions over 4 weeks.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham electroacupuncture treatment, without needle penetration and electrostimulation, 3 times per week for 12 sessions over 4 weeks.
Number of subjects: 62
Study: 27602394

Group type: EXPERIMENTAL
Intervention: Partial thickness double pedicle graft
Number of subjects: 8

Group type: COMPARATOR
Intervention: Full thickness double pedicle graft
Number of subjects: 8
Study: 24463448

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (n = 12)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 18
Study: 23167852

Group type: EXPERIMENTAL
Intervention: Feature-Attribute-Matching-plus-User-Feedback strategy
Number of subjects: 51

Group type: COMPARATOR
Intervention: User-Feedback strategy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Satisfaction survey
Number of subjects: 51
Study: 20625362

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Duloxetine 120 mg/day
Number of subjects: 39
Study: 17646219

Group type: EXPERIMENTAL
Intervention: Prednisone, 2 mg/kg/d up to 60 mg, on days 1 to 5
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 24
Study: 15142875

Group type: EXPERIMENTAL
Intervention: GSTM1‐null genotype
Number of subjects: 114
Study: 11161543

Group type: EXPERIMENTAL
Intervention: Structured triglycerides (ST) emulsion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Long chain triglyceride (LCT) emulsion
Number of subjects: 30
Study: 9831629

Group type: EXPERIMENTAL
Intervention: High fat high cholesterol diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High fat low cholesterol diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low fat low cholesterol diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dietary fat intake
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol-induced percent change in LDL-C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol-induced percent change in HDL-C
Number of subjects: 18
Study: 7853817

Group type: EXPERIMENTAL
Intervention: ditek
Number of subjects: 48

Group type: COMPARATOR
Intervention: disodium cromoglycate (lomudal)
Number of subjects: 48

Group type: COMPARATOR
Intervention: fenoterol (berotek)
Number of subjects: 48
Study: 2506702

Group type: EXPERIMENTAL
Intervention: Neogluconin (2.5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Euglucon (5 mg)
Number of subjects: 25
Study: 414402

Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 31145383

Group type: EXPERIMENTAL
Intervention: Full-body resistance exercise (FB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Upper body resistance exercise (UB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lower body resistance exercise (LB)
Number of subjects: 12
Study: 31392725

Group type: EXPERIMENTAL
Intervention: Seprafilm (two sheets inserted under a midline incision)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (no seprafilm)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 345
Study: 27919627

Group type: EXPERIMENTAL
Intervention: Pemetrexed followed by erlotinib (150 mg orally once daily on days 2-17)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Pemetrexed alone (500 mg/m2 intravenously on day 1)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pemetrexed followed by erlotinib
Number of subjects: 83

Group type: COMPARATOR
Intervention: Pemetrexed alone
Number of subjects: 83
Study: 26033398

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment without abciximab
Number of subjects: 125

Group type: COMPARATOR
Intervention: Clopidogrel treatment with abciximab
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Patients with HRPR
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Patients with low residual platelet reactivity (LRPR)
Number of subjects: 125
Study: 23475636

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab plus docetaxel
Number of subjects: 0
Study: 22176931

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 899
Study: 19692796

Group type: EXPERIMENTAL
Intervention: Ascorbate treatment (intravenous vitamin C)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo treatment (normal saline infusion)
Number of subjects: 38
Study: 16476851

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (unchanged therapy)
Number of subjects: 16
Study: 15379272

Group type: EXPERIMENTAL
Intervention: rhTPO 1.0 microg/(kg x d) administered subcutaneously for up to 14 days after chemotherapy
Number of subjects: 154
Study: 11246381

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intramuscular bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8992351

Group type: EXPERIMENTAL
Intervention: Aggressive treatment to lower LDL cholesterol levels (with lovastatin and, if needed, cholestyramine)
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Moderate treatment to lower LDL cholesterol levels
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Aggressive treatment to lower LDL cholesterol levels
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1351
Study: 8256082

Group type: EXPERIMENTAL
Intervention: Glypressin (intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3547298

Group type: EXPERIMENTAL
Intervention: Buffy coat transfusions (15 mL/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plasma and blood products
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observation (no intervention)
Number of subjects: 20
Study: 31978565

Group type: EXPERIMENTAL
Intervention: PDT + SRP
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: SP + SRP
Number of subjects: 73

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 73
Study: 30808316

Group type: EXPERIMENTAL
Intervention: 1% Povidone-Iodine (PI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2.5% Povidone-Iodine (PI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 5% Povidone-Iodine (PI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no pre-application)
Number of subjects: 21
Study: 27650536

Group type: EXPERIMENTAL
Intervention: Acetagastrodin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 92
Study: 24998617

Group type: EXPERIMENTAL
Intervention: LI-BFR (low-intensity with blood flow restriction)
Number of subjects: 17

Group type: COMPARATOR
Intervention: HI (high-intensity resistance exercise)
Number of subjects: 17
Study: 23163616

Group type: EXPERIMENTAL
Intervention: Larazotide acetate 1 mg
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Larazotide acetate 4 mg
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Larazotide acetate 8 mg
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 21994147

Group type: EXPERIMENTAL
Intervention: Xylitol nasal irrigation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline nasal irrigation
Number of subjects: 20
Study: 18474495

Group type: EXPERIMENTAL
Intervention: EFV + TDF/FTC
Number of subjects: 402
Study: 16566674

Group type: EXPERIMENTAL
Intervention: Auricular acupressure plus Internet-assisted smoking cessation program
Number of subjects: 2

Group type: COMPARATOR
Intervention: Auricular acupressure only
Number of subjects: 2
Study: 15198998

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Body conditioning (placebo control)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal care control group
Number of subjects: 120
Study: 11390253

Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT) 1-g doses
Number of subjects: 9

Group type: COMPARATOR
Intervention: promethazine (active placebo) 50-mg doses
Number of subjects: 9
Study: 9415535

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone (1000 mg per day) for five days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 8301876

Group type: EXPERIMENTAL
Intervention: TJ-960 (7.5 g per day for 8 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TJ-960
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no change in regimen)
Number of subjects: 26
Study: 3771949

Group type: EXPERIMENTAL
Intervention: Uniphyl, 800 mg four times a day (qd)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: metered-dose albuterol, active, 180 micrograms four times a day (qid)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Uniphyl, 400 mg twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Uniphyl, 800 mg qd; placebo, two puffs qid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Uniphyl, 400 mg twice daily; placebo, two puffs qid
Number of subjects: 28
Study: 28933653

Group type: EXPERIMENTAL
Intervention: Navigated women (741)
Number of subjects: 2536

Group type: COMPARATOR
Intervention: Non-navigated women (1,795)
Number of subjects: 2536
Study: 27393499

Group type: EXPERIMENTAL
Intervention: Erlotinib with gemcitabine/platinum
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo with gemcitabine/platinum
Number of subjects: 256
Study: 25588394

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg 1 time per day for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg 1 time per day for 7 days followed by 500 mg 1 time per week for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long-term adjunctive azithromycin
Number of subjects: 60
Study: 22447637

Group type: EXPERIMENTAL
Intervention: Brief interpersonal psychotherapy (IPT-B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 53
Study: 19891803

Group type: EXPERIMENTAL
Intervention: Bipolar-I disorder (BP-I) probands
Number of subjects: 487

Group type: COMPARATOR
Intervention: Attention deficit hyperactivity disorder (ADHD) probands
Number of subjects: 487

Group type: COMPARATOR
Intervention: Healthy control probands
Number of subjects: 487
Study: 18217152

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for six months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical treatment (control group)
Number of subjects: 100
Study: 11332168

Group type: EXPERIMENTAL
Intervention: Smoking mothers
Number of subjects: 203
Study: 9568663

Group type: EXPERIMENTAL
Intervention: Laparoscopic sutured repair
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open omental repair
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 7871647

Group type: EXPERIMENTAL
Intervention: Progressive myopia
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Open-angle glaucoma
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (without ocular diseases)
Number of subjects: 248
Study: 2901125

Group type: COMPARATOR
Intervention: Flupentixol 1 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flupentixol 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flupentixol 1 mg + Diazepam 15 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31032524

Group type: EXPERIMENTAL
Intervention: Magnetic-Controlled Capsule Endoscopy (MCE)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Middle-aged group (control)
Number of subjects: 98
Study: 29091217

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Cobicistat-boosted elvitegravir (150/150 mg)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Modified ITT analysis (lopinavir/ritonavir)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Modified ITT analysis (elvitegravir/cobicistat)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 157

Group type: COMPARATOR
Intervention: Seroconversion
Number of subjects: 157
Study: 26863333

Group type: EXPERIMENTAL
Intervention: Prostaglandin vaginal inserts (dinoprostone 10 mg, misoprostol 50 mcg or 100 mcg)
Number of subjects: 1308
Study: 23333174

Group type: EXPERIMENTAL
Intervention: Total Shoulder Replacement (TSR)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 33
Study: 21467183

Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 150% of individual electrical phosphene threshold (EPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 66% of individual electrical phosphene threshold (EPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 18419630

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg oral suspension once daily
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo oral suspension once daily
Number of subjects: 270
Study: 16864931

Group type: EXPERIMENTAL
Intervention: ARB plus spironolactone (SPRL) 25 mg/day for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: ARB (candesartan 8 mg/day) for 1 year
Number of subjects: 70
Study: 12620527

Group type: EXPERIMENTAL
Intervention: Low fat diet (15% of energy from fat with maintenance of energy intake)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low energy diet (25% energy reduction with maintenance of percentage of energy from fat)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined low fat and low energy diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 41
Study: 10846272

Group type: EXPERIMENTAL
Intervention: Advance telephone prompt
Number of subjects: 179

Group type: COMPARATOR
Intervention: Advance letter prompt only
Number of subjects: 179
Study: 9335081

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8227490

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30325776

Group type: EXPERIMENTAL
Intervention: Cash transfers (∼$11 per month for ≤6 months, conditional on visit attendance)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Food transfers (∼$11 per month for ≤6 months, conditional on visit attendance)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) services
Number of subjects: 805
Study: 30573551

Group type: EXPERIMENTAL
Intervention: Strangulation
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 175
Study: 26983672

Group type: EXPERIMENTAL
Intervention: Resistance training (Arm A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Passive physical therapy (Arm B)
Number of subjects: 60
Study: 24963567

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Conventional follow-up (control)
Number of subjects: 441
Study: 22854050

Group type: EXPERIMENTAL
Intervention: Activated HER-receptors (pHER1, pHER2, pHER3)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: HER2
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Other HER-family members
Number of subjects: 1062
Study: 20669668

Group type: EXPERIMENTAL
Intervention: Ningxintong Granule (NXTG) combined with Western medical conventional treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Western medical conventional treatment alone
Number of subjects: 76
Study: 18544991

Group type: EXPERIMENTAL
Intervention: Docetaxel given on a 3-week schedule
Number of subjects: 0
Study: 16723056

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure at 10 mbar
Number of subjects: 72

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure at 0 mbar
Number of subjects: 72

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure at 5 mbar
Number of subjects: 72
Study: 12483420

Group type: EXPERIMENTAL
Intervention: Myocardial imaging with [N-methyl (11)C]meta-hydroxyephedrine ((11)C-HED) and positron emission tomography (PET)
Number of subjects: 7
Study: 10984081

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingual)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg single dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8571990

Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler velocimetry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1281046

Group type: EXPERIMENTAL
Intervention: EDX-L (epirubicin-lipiodol emulsion)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EDX-L followed by GS (gelatin sponge)
Number of subjects: 18

Group type: COMPARATOR
Intervention: DX-L (doxorubicin-lipiodol emulsion)
Number of subjects: 18

Group type: COMPARATOR
Intervention: GS (gelatin sponge only)
Number of subjects: 18
Study: 3969014

Group type: EXPERIMENTAL
Intervention: Calcitonin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin alternating with growth hormone (combined treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Calcitonin)
Number of subjects: 0
Study: 30040016

Group type: EXPERIMENTAL
Intervention: 3 weeks of textured balance board training (1 minute daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 6 weeks of textured balance board training (1 minute daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Baseline scores for dancers with PAS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison between dancers with and without chronic ankle instability
Number of subjects: 42
Study: 29489681

Group type: EXPERIMENTAL
Intervention: PO-based administration set
Number of subjects: 9

Group type: COMPARATOR
Intervention: PU-based administration set
Number of subjects: 9

Group type: COMPARATOR
Intervention: PVC-based administration set
Number of subjects: 9
Study: 27103982

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at a target dose of 60 mg/kg/day in three divided doses
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) and Placebo
Number of subjects: 31
Study: 24453077

Group type: EXPERIMENTAL
Intervention: RBC EPA + DHA (omega‐3 index)
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: RBC DHA
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: RBC EPA
Number of subjects: 1111
Study: 23342619

Group type: EXPERIMENTAL
Intervention: Cytoflavin (in infusion, then oral administration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline therapy (alpha1‐adrenoblockers, non‐specific anti‐inflammatory drugs, digital prostate massage and vacuum phallostimulation)
Number of subjects: 60
Study: 20175053

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus half saline
Number of subjects: 72

Group type: COMPARATOR
Intervention: Half saline alone
Number of subjects: 72
Study: 17703122

Group type: EXPERIMENTAL
Intervention: In-home psychotherapy for depressive symptoms; details on dosage and duration not specified.
Number of subjects: 0
Study: 16325694

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 452

Group type: COMPARATOR
Intervention: Surgery-first strategy
Number of subjects: 452

Group type: COMPARATOR
Intervention: Angioplasty-first strategy
Number of subjects: 452

Group type: COMPARATOR
Intervention: Health-related quality of life
Number of subjects: 452

Group type: COMPARATOR
Intervention: Hospital costs
Number of subjects: 452
Study: 11990204

Group type: EXPERIMENTAL
Intervention: Neuroblastoma cell bioassay for ciguatoxins
Number of subjects: 111

Group type: COMPARATOR
Intervention: Asymptomatic negative controls
Number of subjects: 111

Group type: COMPARATOR
Intervention: Symptomatic negative controls
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Potential ciguatoxic patients
Number of subjects: 111
Study: 9485250

Group type: EXPERIMENTAL
Intervention: Centrifugal vortex pump
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard roller pump
Number of subjects: 41
Study: 7715941

Group type: EXPERIMENTAL
Intervention: Outpatient cognitive-behavioural therapy (CBT) with amitriptyline (AMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive therapy with amitriptyline (AMI)
Number of subjects: 0
Study: 2611615

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) (Roferon A, Roche, Basle, Switzerland) 18 x 10(6) u i.m. 3 times/week
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of IFN with vinblastine (0.1 mg/kg every third week)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 49
Study: 299841

Group type: EXPERIMENTAL
Intervention: Splenorenal anastomosis
Number of subjects: 225

Group type: COMPARATOR
Intervention: Portocaval anastomosis
Number of subjects: 225

Group type: COMPARATOR
Intervention: Mesentericocaval anastomosis
Number of subjects: 225

Group type: COMPARATOR
Intervention: Palliative operations
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conservative therapeutic approaches
Number of subjects: 225
Study: 30945426

Group type: EXPERIMENTAL
Intervention: Experiential education programme (3 lessons)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120